The purpose of this study is to determine whether identification of misfolded proteins in the skin will help to determine what sort of parkinsonism someone has. We seek to demonstrate whether someone has a synucleinopathy such as Parkinson's disease (PD), multiple system atrophy (MSA), or dementia with Lewy bodies(DLB), as opposed to a tauopathy such as progressive supranuclear palsy (PSP) or corticobasal degeneration (CBD) or no parkinsonism at all (control).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Amount of alpha-synuclein in the skin
Timeframe: Cross-sectional at baseline
Change in PSPRS measures of progressive supranuclear palsy (PSP) severity in people with PSP
Timeframe: Baseline, 1 year, and optional 2 year assessment
Change in UMSARS measures of multiple system atrophy (MSA) severity in people with MSA
Timeframe: Baseline, 1 year, and optional 2 year assessment
Change in Hoehn and Yahr (H&Y) and modified H&Y Scores
Timeframe: Baseline, 1 year, and optional 2 year assessment
Change in Schwab and England (S&E) Score
Timeframe: Baseline, 1 year, and optional 2 year assessment